A
Arthur A. Vandenbark
Researcher at Oregon Health & Science University
Publications - 134
Citations - 7372
Arthur A. Vandenbark is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Experimental autoimmune encephalomyelitis & T cell. The author has an hindex of 41, co-authored 134 publications receiving 6920 citations. Previous affiliations of Arthur A. Vandenbark include Veterans Health Administration & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Regulatory CD8+CD122+ T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells
Sheetal Bodhankar,Sheetal Bodhankar,Yingxin Chen,Andrew Lapato,Andrew Lapato,Arthur A. Vandenbark,Arthur A. Vandenbark,Stephanie J. Murphy,Julie A. Saugstad,Halina Offner,Halina Offner +10 more
TL;DR: A major neuroprotective role for IL-10+ B-cells is demonstrated in treating MCAO in male WT mice at a time point well beyond the ~4 h tPA treatment window, leading to the generation of a dominant IL- 10+CD8+CD122+ Treg population associated with spleen preservation and reduced CNS inflammation.
Journal ArticleDOI
Assessment of Reactivity to Tumor Extracts by Leukocyte Adherence Inhibition and Dermal Testing
Burger Dr,Arthur A. Vandenbark,Patricia Finke,Arthur Malley,Maureen Frikke,John A. Black,Karen M. Acott,Don Begley,R. Mark Vetto +8 more
Journal ArticleDOI
CCR6: a biomarker for Alzheimer's-like disease in a triple transgenic mouse model
Sandhya Subramanian,Patricia Ayala,Patricia Ayala,Teri L. Wadsworth,Christopher J. Harris,Arthur A. Vandenbark,Arthur A. Vandenbark,Joseph F. Quinn,Joseph F. Quinn,Halina Offner,Halina Offner +10 more
TL;DR: The authors' data demonstrate increased expression of CCR6 in the brain and peripheral immune organs of both pre-symptomatic and symptomatic 3xTg-AD mice, strongly suggesting an ongoing inflammatory process that precedes onset of clinical AD-like disease.
Journal ArticleDOI
Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury.
Halina Offner,Halina Offner,Sandhya Subramanian,Chunhe Wang,Michael Afentoulis,Arthur A. Vandenbark,Arthur A. Vandenbark,Jianya Huan,Gregory G. Burrows +8 more
TL;DR: Pronounced IL-13 levels coupled with marked reduction in IL-6 levels secreted by PLP-specific T cells from blood after treatment of mice with RTL401 indicate that IL- 13 and IL- 6 may be useful markers for following effects of RTL therapy in future clinical trials in multiple sclerosis.
Journal ArticleDOI
Regulation of Encephalitogenic T Cells with Recombinant TCR Ligands
Gregory G. Burrows,Kirsten Adlard,Bruce F. Bebo,Justin W. Chang,Kirill Tenditnyy,Arthur A. Vandenbark,Arthur A. Vandenbark,Halina Offner +7 more
TL;DR: Clinical effects of recombinant TCR ligands (RTLs) comprised of the rat RT1.B β1α1 domains covalently linked to the 72–89 peptide of guinea pig myelin basic protein (RTl-201), to the corresponding 72– 89 peptide from rat myelinbasic protein ( RTL-200), or to cardiac myosin peptide CM-2 (RT L-203).